Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VTUS followed $ heff into this. Meeting with Fda june
Form 4 6:30 pm
Etrm $heff feels will not use shelf soon. Hope he is right. I chose to avg down lynx instead of etrm over last two weeks.
Market seems to think shelf will not be used until after adcom. Can we break 2 in the next week?
news
CombiMatrix Services Available Through LI Path to Tri-State Area in Northeast
IRVINE, Calif., May 13, 2014 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that Long Island Pathology (LI Path) is now offering its patients CombiMatrix's chromosomal microarray analysis (CMA) testing for miscarriage analysis. LI Path, based in East Setauket, New York, is a physician-led diagnostic pathology laboratory serving the New York, New Jersey and northeastern Pennsylvania areas.
LI Path, which is currently in the midst of an expansion initiative, is an established part of the regional clinical and anatomic pathology network in the Tri-State area around New York. Gynecologic pathology is one of LI Path's specialties.
"Patients are becoming much more advanced in their knowledge and awareness of how genetic testing can provide them important information about their pregnancies, and we are very excited to be able to offer CMA testing to help them understand the potential genetic cause of a failed pregnancy and factors for their continued efforts," said Hal Rose, Managing Partner of LI Path, which in addition to its main laboratory in East Setauket also has a satellite laboratory in Southampton, New York. LI Path provides testing for physicians, hospital laboratories, endoscopy centers and surgery centers. "We believe in the growing importance and clinical advantages of CMA and look forward to working with CombiMatrix."
CombiMatrix President and CEO Mark McDonough noted that the relationship with LI Path is an important part of the Company's strategy to build on its advantageous position and success in CMA testing and to focus on laboratory partnerships.
"Building relationships with regional labs like LI Path is a key part of our national growth strategy, particularly those that specialize in gynecological pathology," McDonough said. "Miscarriage analysis is a rapidly growing testing market and, as in other areas of prenatal genetic analysis, microarray analysis is becoming the standard of care."
Miscarriage analysis testing, also called Products of Conception testing, is a subset of the overall prenatal testing market. It allows OB/GYN physicians and clinicians to better determine if there is a genetic cause for a miscarriage or other related event.
About LI Path
LI Path is an independent diagnostic and consultative clinical and anatomic pathology laboratory located in East Setauket and Southampton, New York. LI Path is dedicated to providing top level diagnostic pathology services in a cost effective and efficient manner. The laboratory's pathologists are certified by the American Board of Pathology with multiple areas of sub-specialties and are active members of the community. Additional information about LI Path is available at www.lipath.com or by calling 1-(888)-454-7284
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in miscarriage analysis, prenatal testing and pediatric genetics, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques, including chromosomal microarray, standardized and customized fluorescence in situ hybridization ("FISH") and high-resolution karyotyping. CombiMatrix is dedicated to providing high-level clinical support for healthcare professionals in order to help them incorporate the results of complex genetic testing into patient-centered medical decision making. Additional information about CombiMatrix is available at www.combimatrix.com or by calling 1-800-710-0624.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations, speak only as of the date hereof and are subject to change. All statements, other than statements of historical fact included in this press release, are forward-looking statements. Forward-looking statements can often be identified by words such as "anticipates," "expects," "intends," "plans," "goal," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "could," "potential," "continue," "ongoing," "objective," similar expressions, and variations or negatives of these words and include, but are not limited to, statements regarding the access to our services for LI Path physicians. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. The risks and uncertainties referred to above include, but are not limited to: use of our services by LI Path patients; market acceptance of CMA as a superior method of molecular diagnostic testing; our ability to successfully expand the base of our customers and strategic partners, add to the menu of our diagnostic tests in both of our primary markets, develop and introduce new tests and related reports, optimize the reimbursements received for our testing services, and increase operating margins by improving overall productivity and expanding sales volumes; our ability to successfully accelerate sales, allow access to samples earlier in the testing continuum, steadily increase the size of our customer rosters in both developmental medicine and oncology; our ability to attract and retain a qualified sales force; rapid technological change in our markets; changes in demand for our future products; legislative, regulatory and competitive developments; general economic conditions; and various other factors. Further information on potential factors that could affect our financial results is included in our Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, except as required by law.
Read more: http://www.nasdaq.com/press-release/combimatrix-announces-li-path-now-offering-companys-miscarriage-analysis-testing-20140513-00160#ixzz31bB4GrqD
pgnx Adcom official. Hope this starts to move now. Need to break some resistance
cbmx news
CombiMatrix Services Available Through LI Path to Tri-State Area in Northeast
IRVINE, Calif., May 13, 2014 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that Long Island Pathology (LI Path) is now offering its patients CombiMatrix's chromosomal microarray analysis (CMA) testing for miscarriage analysis. LI Path, based in East Setauket, New York, is a physician-led diagnostic pathology laboratory serving the New York, New Jersey and northeastern Pennsylvania areas.
LI Path, which is currently in the midst of an expansion initiative, is an established part of the regional clinical and anatomic pathology network in the Tri-State area around New York. Gynecologic pathology is one of LI Path's specialties.
"Patients are becoming much more advanced in their knowledge and awareness of how genetic testing can provide them important information about their pregnancies, and we are very excited to be able to offer CMA testing to help them understand the potential genetic cause of a failed pregnancy and factors for their continued efforts," said Hal Rose, Managing Partner of LI Path, which in addition to its main laboratory in East Setauket also has a satellite laboratory in Southampton, New York. LI Path provides testing for physicians, hospital laboratories, endoscopy centers and surgery centers. "We believe in the growing importance and clinical advantages of CMA and look forward to working with CombiMatrix."
CombiMatrix President and CEO Mark McDonough noted that the relationship with LI Path is an important part of the Company's strategy to build on its advantageous position and success in CMA testing and to focus on laboratory partnerships.
"Building relationships with regional labs like LI Path is a key part of our national growth strategy, particularly those that specialize in gynecological pathology," McDonough said. "Miscarriage analysis is a rapidly growing testing market and, as in other areas of prenatal genetic analysis, microarray analysis is becoming the standard of care."
Miscarriage analysis testing, also called Products of Conception testing, is a subset of the overall prenatal testing market. It allows OB/GYN physicians and clinicians to better determine if there is a genetic cause for a miscarriage or other related event.
About LI Path
LI Path is an independent diagnostic and consultative clinical and anatomic pathology laboratory located in East Setauket and Southampton, New York. LI Path is dedicated to providing top level diagnostic pathology services in a cost effective and efficient manner. The laboratory's pathologists are certified by the American Board of Pathology with multiple areas of sub-specialties and are active members of the community. Additional information about LI Path is available at www.lipath.com or by calling 1-(888)-454-7284
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in miscarriage analysis, prenatal testing and pediatric genetics, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques, including chromosomal microarray, standardized and customized fluorescence in situ hybridization ("FISH") and high-resolution karyotyping. CombiMatrix is dedicated to providing high-level clinical support for healthcare professionals in order to help them incorporate the results of complex genetic testing into patient-centered medical decision making. Additional information about CombiMatrix is available at www.combimatrix.com or by calling 1-800-710-0624.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations, speak only as of the date hereof and are subject to change. All statements, other than statements of historical fact included in this press release, are forward-looking statements. Forward-looking statements can often be identified by words such as "anticipates," "expects," "intends," "plans," "goal," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "could," "potential," "continue," "ongoing," "objective," similar expressions, and variations or negatives of these words and include, but are not limited to, statements regarding the access to our services for LI Path physicians. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. The risks and uncertainties referred to above include, but are not limited to: use of our services by LI Path patients; market acceptance of CMA as a superior method of molecular diagnostic testing; our ability to successfully expand the base of our customers and strategic partners, add to the menu of our diagnostic tests in both of our primary markets, develop and introduce new tests and related reports, optimize the reimbursements received for our testing services, and increase operating margins by improving overall productivity and expanding sales volumes; our ability to successfully accelerate sales, allow access to samples earlier in the testing continuum, steadily increase the size of our customer rosters in both developmental medicine and oncology; our ability to attract and retain a qualified sales force; rapid technological change in our markets; changes in demand for our future products; legislative, regulatory and competitive developments; general economic conditions; and various other factors. Further information on potential factors that could affect our financial results is included in our Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, except as required by law.
Read more: http://www.nasdaq.com/press-release/combimatrix-announces-li-path-now-offering-companys-miscarriage-analysis-testing-20140513-00160#ixzz31bB4GrqD
Can we bust through 4.00 with ad com news? Hope so. Pgnx
Cbmx. I think it oversold and a will be much higher. That being said just looking for a quick bounce to 2.50 area. Some background.
http://www.thestreet.com/story/12532385/2/combimatrix-poised-to-double--or-more.html
Cbmx. Bought small hoping for a little bounce
Had high hopes for this pos. now just hoping to get back to 2.2 and break even.
I have enough too added more at 3.25 yesterday. No more averaging down for me :)
pr released EDT 3:45
Syn. Holding up nicely.
AEZS considering starting a position long term this week. PDUFA long way off but worth getting in at the bottom.
SYN I think with no news today sentiment will be bullish. Still may be a bear raid but this bodes well. I can not see them releasing bad news day of presentation. Up just a tad pre-market. Will be interesting. I have been wrong a lot over the last few months, hoping im right this time.
Syn. Missed my chance to sell some on the news last week. Releasing news week before presentation has me a little worried. Got to stop trying to over think these things. I'm holding because the did not raise cash. Hoping its because they know they can get much better terms after data release.
syn i think it will start to move now. I have been very wrong a lot lately though. You think they will have a pr morning of 29th or wait until the presentation for data?
pgnx bought some more at 3.60 Think this a bargain here. have 2500 shares syn glad to see its moving. Have a few weeks to see how much to hold thru data on 29th. Think it has room to go.
Etrm. I averaged down as much as I can lol. Gonna have to wait this one out.
ot stuck in a lot of positions. I know that they will bounce back. Upset with my self for not cutting losses and putting in stop losses especially with ETRM.
Hopefully the $heff affect will help my portfolio. I added 300 shares pgnx and still holding way too much ETRM and SYN.
Syn added 1000 2.45
Pgnx bought starter yesterday @ 4.17. Still waiting for syn and gtxi to rebound. Not a loss till I sell. Constant learning process, should have had stop losses on these as I could have reloaded at lower level. Oh we'll I am confident that pps will move up towards end of month catalysts.
I expect a bear raid at some point with extreme volatility on approval day with mm taking out stops losses. There is possibility of extension which would only be for labeling purposes but that would have to happen by Tuesday, just my opinion. We may touch 5.80 today, expect an s.a bash piece to come out since paid analyst price targets did not work.
My thought is hedges are accumulating, they will sell off partially to push pps down, scare off retail and then buy more. They know the game and will figure out some way to end up on top. I'm hoping that their plan is to push pps thru roof after approval and try to short it down after. In that scenarios I can trade in and out days after approval. Just a bunch of thoughts, I guess we shall see.
Mnkd. Two weeks for shorts to cover. Going to be some crazy volatility on approval date. I'll probably be on the sidelines unless I pick up some on a bear raid.
Mnd. I have a bunch mood "stink" bids in in case it is manipulated.
Syn. Knew I should have sold in pre market. No foolin I think all my holdings will be in green tomorrow.
Norms watch list
syn (up premarket) trlpf cmbx rgdx ecte gtxi qrxpy
Ot. This week has to be better than last, right?
Syn. Got some but unfortunately my largest holding is etrm. Gonna have to be patient, lesson learned to my much capital in one stock. Really thought we would rebound late in week.
Qrxpy
FDA Sets 22 April 2014 For Moxduo® Advisory Committee Meeting
SYDNEY and BEDMINSTER, N.J., March 24, 2014 /PRNewswire-USNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the United States Food and Drug Administration (FDA) has set 22 April 2014 as the date of the Advisory Committee meeting to consider the Company's resubmitted Moxduo New Drug Application (NDA).
"As previously announced, our PDUFA date is 25 May, 2014," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "We look forward to presenting to the Advisory Committee the Moxduo clinical data as outlined in our New Drug Application highlighting what the Company believes is Moxduo's respiratory benefit from Study 022."
The Advisory Committee meeting is open to the public and will be held from 8.00am to 5.00pm at the FDA White Oak Conference Center, in Building 31, the "Great Room" (Rm. 1503), 10903 New Hampshire Avenue, Silver Spring, Maryland. The meeting will also be webcast live, the details of which will be provided by the FDA in advance of the meeting.
Additional information can be found on the FDA's website at:
http://www.fda.gov/AdvisoryCommittees/default.htm
or by calling the FDA Advisory Committee Information Line:
+1 800 741 8138 (301 443 0572 in the Washington, DC area)
The Advisory Committee meeting is the next step in the Moxduo approval process. Moxduo, an immediate release Dual Opioid® therapy for the treatment of moderate to severe acute pain, is a patented 3:2 fixed ratio combination of morphine and oxycodone.
About QRxPharma
QRxPharma Limited is an Australian based, commercial-stage specialty pharmaceutical company focused on the development and commercialisation of new pain management and abuse prevention products. Based on a development strategy that focuses on enhancing the clinical utility of currently approved compounds as well as bringing new products to market, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risks and improved patient outcomes. The Company's refiled New Drug Application for its lead product candidate immediate release Moxduo® for the treatment of acute pain, is presently under review at the US Food and Drug Administration. QRxPharma has entered into strategic agreements with Actavis Inc., Paladin Labs Inc., Aspen Group and Teva for the commercialisation of immediate release Moxduo in the US, Canada, Australia (including New Zealand and Oceania), South Africa and Israel. The Company's clinical pipeline includes an intravenous (IV) and controlled release (CR) formulation of Moxduo. QRxPharma is also collaborating with Aesica Formulation Development Limited, for the worldwide promotion of QRxPharma's proprietary Stealth Beadlets™ abuse deterrence technology. For more information, visit www.qrxpharma.com.
Forward Looking Statements
This release contains forward-looking statements. Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations. Any statement in this release that states our intentions, beliefs, expectations or predictions (and the assumptions underlying them) is a forward-looking statement. These statements are based on plans, estimates and projections as they are currently available to the management of QRxPharma. Forward-looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events. By their very nature, forward-looking statements involve risks and uncertainties. A number of important factors could therefore cause actual results to differ materially from those contained in any forward-looking statement. Such factors include risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialisation of the Company's proposed products.
SOURCE QRxPharma Limited
Copyright 2014 PR Newswire
Ad com 4-22 should see some upside from here (3.80)
Qrxpy 3.80 S.A article out recently, just watching but wondering if there will be an ad com ?
Trlpf. Temporarily sold my position to clear funds to buy syn. And avg down gtxi, aezs. Hopefully trlpf remains stagnant while the others rebound. Just have to have a little patience, time will tell.
Qrxpy 3.80 may jump on board tomorrow
Aezs added yesterday at 1.23. Hard to tell how much this can run if the company dilutes heavily on the run up.